Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by the epidermal growth factor. Intravenous and subcutaneous administration of trastuzumab have comparable clinical and pharmacolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Triantafyllidi, Eleni, Triantafillidis, John K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405693/
https://www.ncbi.nlm.nih.gov/pubmed/36009592
http://dx.doi.org/10.3390/biomedicines10082045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405693/
https://www.ncbi.nlm.nih.gov/pubmed/36009592
http://dx.doi.org/10.3390/biomedicines10082045

Ejemplares similares